Lorenzo’s oil is 4 parts of glyceryl trioleate and 1 part glyceryl trierucate, which are the triacylglycerol forms of oleic acid and erucic acid and are prepared from olive oil and rapeseed oil. It is used in the investigational treatment of asymptomatic patients with adrenoleukodystrophy (ALD). The oil was formulated by Augusto and Michaela Odone after their son Lorenzo was diagnosed with the disease in 1984, at the age of five, with the actual production initially developed by retired British scientist Don Suddaby (formerly of Croda International). Suddaby and his colleague, Keith Coupland, received U.S. Patent No. 5,331,009 for the oil. The royalties received by Augusto were paid to the Myelin Project which he and Michaela founded to further research treatments for ALD and similar disorders. The Odones and their invention obtained widespread publicity in 1992 because of the film Lorenzo’s Oil.
Lorenzo's oil costs approximately US $440 for a month's treatment.
In the U.S., Lorenzo's oil is currently available to only the patients taking part in a clinical trial under the direction of the Kennedy Krieger Institute. Thus, Lorenzo's oil can be obtained only through prescription by Kennedy Krieger Institute-authorized physicians. A 500-ml bottle costs approximately $56.00. Some insurance companies will provide coverage for the oil, but others do not because it is still considered an experimental drug by the Food and Drug Administration (FDA).
Proposed mechanism of action
Lorenzo's oil, in combination with a diet low in VLCFA, has been investigated for its possible effects on the progression of ALD. Clinical results have been mixed and the use of Lorenzo's oil has been controversial due to uncertainties regarding its clinical efficacy and the clinical indications for its use.
Hugo Moser played a prominent role in both the treatment of Lorenzo Odone and the scientific evaluation of Lorenzo's oil. In 2005, Moser published a controlled study concluding that Lorenzo's oil does not alter the course of the illness in symptomatic patients, but asymptomatic patients had a reduced risk of developing ALD while on the dietary therapy. Moser appraised Lorenzo's oil again in a 2007 report.
A study by Poulos published in 1994 found that Lorenzo's oil is of limited value in correcting the accumulation of saturated VLCFAs in the brain of patients with ALD. Comparative autopsies showed that treatment enriched erucic acid in plasma and tissues, but not in the brain.
Dietary manipulation using Lorenzo's oil has been shown to lower blood levels of very-long-chain fatty acids, but it is ineffective in symptomatic ALD. However, studies by Dr. Hugo Moser have found evidence that use of the oil by asymptomatic patients may slightly delay the onset of symptoms.
- Shankar Vedantam. "A Real-Life Sequel to 'Lorenzo's Oil' - washingtonpost.com". Washington Post 2007-01-28. pp. A01. Retrieved 2007-12-10.
- The Telegraph - Lorenzo Odone obituary
- U.S. Patent 5,331,009: Pharmaceutical compositions for treating adrenoleukodystrophy. Issued July 19, 1994.
- "Lorenzo's Oil boy is dead at 30". BBC News. 31 May 2008. Retrieved 2008-06-02.
- "Subject of 'Lorenzo's Oil' dies at 30". CNN. Associated Press. 2008-05-30. Archived from the original on July 17, 2008. Retrieved 2008-07-12.
- "Lorenzo's Oil - The Oil". The Myelin Project. Retrieved 3 November 2012.
- "Lorenzo's Oil - The Oil, How to get the oil". The Myelin Project. Retrieved 3 November 2012.
- Berger J, Pujol A, Aubourg P, Forss-Petter S (July 2010). "Current and Future Pharmacological Treatment Strategies in X-Linked Adrenoleukodystrophy". Brain Pathol. 20 (4): 845–56. PMC . PMID 20626746. doi:10.1111/j.1750-3639.2010.00393.x.
- Moser HW, Raymond GV, Lu SE, Muenz LR, Moser AB, Xu J, Jones RO, Loes DJ, Melhem ER, Dubey P, Bezman L, Brereton NH, Odone A (July 2005). "Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's Oil". Archives of Neurology. 62 (7): 1073–80. PMID 16009761. doi:10.1001/archneur.62.7.1073.
- Moser HW, Moser AB, Hollandsworth K, Brereton NH, Raymond GV (September 2007). ""Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy". J. Mol. Neurosci. 33 (1): 105–13. PMID 17901554. doi:10.1007/s12031-007-0041-4.
- Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaqué I, Jakobezak C, Lemaitre A, Boureau F, Wolf C (September 1993). "A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy". N. Engl. J. Med. 329 (11): 745–52. PMID 8350883. doi:10.1056/NEJM199309093291101.
- van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B, Wanders RJ, Barth PG (September 1999). "Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil"". J. Neurol. Neurosurg. Psychiatr. 67 (3): 290–9. PMC . PMID 10449548. doi:10.1136/jnnp.67.3.290.
- Poulos A, Gibson R, Sharp P, Beckman K, Grattan-Smith P (1994). "Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil". Ann. Neurol. 36 (5): 741–6. PMID 7979219. doi:10.1002/ana.410360509.
- Magnhild Rasmussen; Ann B. Moser; Janet Borel; Surinder Khangoora; Hugo W. Moser (Aug 1994). "Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's Oil)". Neurochemical Research. Springer Netherlands. 19 (8): 1073–1082. PMID 7800117. doi:10.1007/BF00968719.
- Crowther MA, Barr RD, Kelton J, Whelan D, Greenwald M (February 1995). "Profound thrombocytopenia complicating dietary erucic acid therapy for adrenoleukodystrophy". American Journal of Hematology. 48 (2): 132–3. PMID 7847331. doi:10.1002/ajh.2830480217.
- Luger CL et al. Food Safety and Foodborne Toxicants. Chapter 14 in Hayes' Principles and Methods of Toxicology, Sixth Edition. Eds A. Wallace Hayes, Claire L. Kruger. CRC Press, 2014 ISBN 9781842145371. Quote: "In humans. however. although the long-term use of Lorenzo's oil (oleic acid and erucic acid) in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy leads to thrombocytopenia and lymphopenia (Unkrig et al. 1994), adverse effects from dietary consumption of erucic acid have not been reported."
- Food Standards Australia New Zealand (June 2003) Erucic acid in food Archived 2008-12-03 at the Wayback Machine. : A Toxicological Review and Risk Assessment . Technical report series No. 21; Page 4 paragraph 1; ISBN 0-642-34526-0, ISSN 1448-3017
- "Food Standards Agency - Agency issues warning on erucic acid". 2 September 2004. Retrieved 2007-11-02.